832 results on '"Heckman, Caroline"'
Search Results
2. Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma
3. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones
4. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling
5. Robust scoring of selective drug responses for patient-tailored therapy selection
6. Genetic and functional analysis of Raynaud’s syndrome implicates loci in vasculature and immunity
7. Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia
8. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
9. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia
10. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial
11. Personalizing precision medicine: Patients with AML perceptions about treatment decisions
12. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
13. An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
14. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia
15. Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia
16. Bipartite network models to design combination therapies in acute myeloid leukaemia
17. Improving drug sensitivity predictions in precision medicine through active expert knowledge elicitation
18. Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window
19. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
20. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
21. Prognostic significance of esterase gene expression in multiple myeloma
22. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
23. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
24. Venetoclax triggers sub-lethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
25. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition
26. FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
27. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
28. Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
29. Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
30. KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia
31. Robust scoring of selective drug responses for patient-tailored therapy selection
32. Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
33. A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow
34. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML
35. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
36. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting
37. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
38. S175: SINGLE-CELL ANALYSIS REVEALS SOMATIC TP53 MUTATIONS EMERGE IN EARLY PROGENITOR CELLS BUT BECOME ENRICHED IN THE ERYTHROID LINEAGE IN ERCC6L2 DISEASE
39. P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
40. PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
41. P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
42. Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
43. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
44. Germline alterations in a consecutive series of acute myeloid leukemia
45. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling
46. Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
47. Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
48. Data from Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
49. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
50. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.